Methods of treating cancer
OwnerDavid A. Potterinventor
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.
Claims60
A method for treating an HIV-negative patient who has cancer, the method comprising administering to the patient a therapeutically effective amount of a composition comprising
- (a) a compound of Formula I
- 5
- (b) ai compound of Formula II
- 6
- (c) a compound of Formula III
- 7
- (d) a compound of Formula IV
- 8
- (e) a compound of formula V
- 9
- (f) a pharmaceutically acceptable salt of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V;
- (g) a prodrug of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V.
A method of predicting whether a patient who has cancer will respond to treatment with a composition comprising a calpain inhibitor, the method comprising:
- (a) providing cells from a cancer cell line that is a model of the type of cancer the patient has and
- (b) determining
- (i) the level of expression or activity of m-calpain or
- (ii) the level of expression or activity of an EGF receptor
- in cells of the cell line, wherein a level m-calpain or of an EGF receptor that is higher than the level of expression or activity of m-calpain or an EGF receptor, respectively, in a reference cell, or population of reference cells, indicates that the patient is less likely to respond positively if treated with a composition comprising a calpain inhibitor.
A method of predicting whether a patient who has cancer will respond to treatment with a composition comprising a calpain inhibitor, the method comprising:
- (a) providing cancerous cells from the patient and
- (b) determining
- (i) the level of expression or activity of m-calpain or
- (ii) the level of expression or activity of an EGF receptor
- in the cancerous cells from the patient, wherein a level that is higher than the level of expression or activity of m-calpain or an EGF receptor, respectively, in a reference cell, or population of reference cells, indicates that the patient is less likely to respond positively if treated with a composition comprising a calpain inhibitor.
A method of selecting a treatment regime for a patient who has cancer, the method comprising:
- (a) providing cells from a cancer cell line that is a model of the type of cancer the patient has or providing cancerous cells from the patient
- (b) exposing the cells from the cell line or the cancerous cells from the patient to at least two different compositions comprising a calpain inhibitor and
- (c) determining which, if any, of the at least two different compositions is most effective in killing the cells from the cell line or the cancerous cells from the patient, reducing the motility of those cells, or reducing the rate at which they grow or proliferate.
56 The method of claim 31, wherein the level of m-calpain or the level of an EGF receptor is measured by assessing m-calpain or EGF receptor protein, respectively.
57 A method of treating an HIV-negative patient who has cancer comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of Formula I or a pharamaceutically acceptable salt or prodrug thereof, and a proteasome inhibitor.
58 The method of claim 57 wherein the proteasome inhibitor is bortezomib.
59 A method of treating an HIV-negative patient who has cancer comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of Formula I or a pharamaceutically acceptable salt or prodrug thereof, and a Cox-2 inhibitor.
60 A method of treating an HIV-negative patient who has cancer comprising administering to the patient a therapeutically effective amount of a composition comprising a compound of Formula I or a pharamaceutically acceptable salt or prodrug thereof, and docetaxel.
Dependencies are inferred from the claim text.